MARKET NEWS

Q BioMed Signs Distribution Agreement With isoSolutions for the Sales of Strontium89 in Canada
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of COVID-19 Infection & Associated Coagulopathy With rNAPc2
Catalent to Supply Edenbridge Pharmaceuticals With a Fast-Dissolve Zydis Formulation of Glycopyrrolate Intended as Adjunctive Therapy for Patients With Peptic Ulcer
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma
Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Study of FTX-6058 for Sickle Cell Disease
Sensirion Expands its Flow Sensor Portfolio for Ventilators
Apollomics Doses First Patient in a Phase 1 Clinical Trial of APL-102
DFE Pharma Demonstrates Impact of Powder Properties on the Rheological Behavior of Excipients

  COMPANY PROFILE

As a world-leading drug device combination solutions specialist, our purpose of putting patients first enables us to design and manufacture devices that maximize treatment efficacy. We are the utmost holistic partner and help our customers succeed in the sprint to market. From early device strategy to state-of-the-art manufacturing, we’re committed to the highest quality standards. Agile and open-minded, we work with our customers as colleagues. Together, we go the extra mile to fulfill our mission. Nemera offers a comprehensive portfolio of products and services covering several key delivery routes. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Dotmatics to Deliver the Foundation for Croda’s R&D Digital Program: Artificial Intelligence & Data Mining

Dotmatics to Deliver the Foundation for Croda’s R&D Digital Program: Artificial Intelligence & Data Mining

Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory data workflows for scientific discovery and innovation research, recently announced it has been selected….

VERAXA Biotech & Indivumed Cooperate on the Development of Precision Oncology Antibody

VERAXA Biotech & Indivumed Cooperate on the Development of Precision Oncology Antibody

VERAXA Biotech GmbH, Heidelberg, and Indivumed GmbH, Hamburg, recently announced their agreement to jointly discover modulatory and functional antibodies against several targets that are relevant for….

Daré Bioscience Announces FDA Acceptance & Priority Review of NDA for DARE-BV1 for the Treatment of Bacterial Vaginosis

Daré Bioscience Announces FDA Acceptance & Priority Review of NDA for DARE-BV1 for the Treatment of Bacterial Vaginosis

Daré Bioscience, Inc. recently announced the US FDA accepted for filing the company’s New Drug Application (NDA) for DARE-BV1 for the treatment of bacterial vaginosis…..

Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders

Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders

Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

August 25 – Transdermal/Topical Delivery
September 1 – Drug Delivery